Journal of neuroimmunology
B cell tolerance checkpoint function in multiple sclerosis and transient CD52 depletion.
Anastasia Alexaki, Fotis Baltoumas, Dimitrios Tzanetakos, Chrysoula Zografou, Theodoros Dame, Chrysoula Michaletou, Galini Kyriakaki, Aglaia G Vakrakou, Maria Anagnostouli, Georgia Karadima, Marianna Tzanoudaki, Marinos C Dalakas, Leonidas Stefanis, Konstantinos Kilidireas, Kevin C O'Connor
Published: 202610.1016/j.jneuroim.2026.578854
Abstract
Transient CD52 immune cell depletion with the monoclonal antibody alemtuzumab is highly effective in treating relapsing-remitting multiple sclerosis but often leads to secondary autoimmunity. Whether these effects are linked to an alteration of B cel…
Preview only. Read the full abstract at the source